Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Pediatric cancer immunotherapy has expanded from anti-GD2 antibodies and bispecific T-cell engagers to immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. These treatments can produce rapid, nonlinear, and partially overlapping toxicities, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infection, prolonged cytopenia, B-cell aplasia, and organ-specific immune-related adverse events.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
